NCT06635746
Dose Escalation Study of Vinpocetine in Healthy Volunteers
At risk: Primary completion moved at least 6 months later, primary endpoint(s) modified, and 1 more.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion pushed from Jun 1, 2026 to Dec 31, 2026 Show 8 more changesShow less
- Primary endpoint(s) modified
- Start date changed from estimate of Jun 1, 2025 to Oct 1, 2025
- Eligibility criteria expanded, about 10 words
- Trial status changed: Unknown → Recruiting
- Enrollment reduced: 20 → 16 participants
- Trial arms changed: 1 → 2
- Study sites: 0 to 1
- Secondary endpoints expanded, about 2 words
- Minor Changed Registry marked status Unknown; last known: Not Yet Recruiting
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (1)
Arms and interventions
Participants will take increasing, single doses of vinpocetine to determine maximum tolerated dose (MTD) based on intolerable side effects. 10 healthy volunteers enrolled, consented and screened; 4 patients failed screening; 6 subjects have taken study drug as single ascending doses. At 350mg dose, 6 subjects tested - 1/6 with intolerable side effect (vomiting). At 400mg dose, 2 subjects had marked nausea. Maxium Tolerated Dose = 350mg single dose. Six subjects to be enrolled in the TID dosing study.
After completion of single dose MTD study, 6 healthy volunteers will receive TID doses to determine PK of TID dosing using blood concentrations.
Drugs: Vinpocetine
Sites
1 site in 1 country
- Stanford UniversityPalo Alto, California, United States